Correction to: Cycloartane triterpenoid (23R, 24E)-23-acetoxymangiferonic acid inhibited proliferation and migration in B16-F10 melanoma via MITF downregulation caused by inhibition of both ß-catenin and c-Raf-MEK1-ERK signaling axis.

The article Cycloartane triterpenoid (23R, 24E)-23-acetoxymangiferonic acid inhibited proliferation and migration in B16-F10 melanoma via MITF downregulation caused by inhibition of both ß-catenin.

Cycloartane triterpenoid (23R, 24E)-23-acetoxymangiferonic acid inhibited proliferation and migration in B16-F10 melanoma via MITF downregulation caused by inhibition of both ß-catenin and c-Raf-MEK1-ERK signaling axis.

We recently reported that (23R, 24E)-23-acetoxymangiferonic acid (23R-AMA), a cycloartane triterpenoid isolated by activity-guided separation from a methanol extract of Garcinia sp. bark, inhibited melanin production via inhibition of tyrosinase (TYR) expression in the B16-F10 melanoma cell line. Since 23R-AMA also inhibited microphthalmia-associated transcription factor (MITF) expression, an upstream factor of TYR, these features of 23R-AMA were thought to be appropriate for development of whitening cosmetics. However, 23R-AMA exhibited growth inhibition other than inhibition of melanin production in B16-F10 cells. Therefore, we investigated biological activities of 23R-AMA in detail, focused on its application as an anti-melanoma compound. In this study, we demonstrated that 23R-AMA inhibited cell proliferation and basic FGF (bFGF)-induced migration in B16-F10 cells. Furthermore, 23R-AMA promoted ser45/thr41 phosphorylation of ß-catenin and suppressed its intranuclear accumulation, which was suggested to be related to inhibition of MITF expression. The transcriptional activity of MITF is known to be regulated by phosphorylation via activated ERK. Further investigation revealed that 23R-AMA inhibited phosphorylation of c-Raf, MEK-1, and ERK, and also that of upstream molecules including FAK and c-Src. These results suggested that 23R-AMA inhibited growth and migration of B16-F10 melanoma by regulating both MITF expression and its activity. The activities of 23R-AMA reported in this study are new aspects of cycloartane triterpenoids.

Screening for natural medicines effective for the treatment of osteoporosis.

Bone-forming osteoblasts are differentiated from mesenchymal stem cells and dysregulation of this differentiation can lead to osteoporosis. Meanwhile, bone-resorbing osteoclasts are both differentiated and multinucleated from hematopoietic precursor cells of monocyte and/or macrophage lineage. Bone resorption inhibitors such as bisphosphonates and estrogen are used to treat osteoporosis. However, the adverse effects of the long-term use of these medicines are of concern, and so the development of new therapies to ameliorate osteoporosis is desirable. Therefore, in the present study, we screened 22 plant extracts and found that nine methanolic extracts of plants promote the differentiation of MC3T3-E1 cells to osteoblasts. These nine extracts were then evaluated for their inhibitory activity on osteoclast differentiation in RAW264.7 mouse macrophage cells. Of the nine extracts, Daucus carota, Vitis spp., Sasa veitchii, Euptelea polyandra, and Sesamum indicum exhibited pro-osteoblastic and anti-osteoclastic activity with low cytotoxicity, suggesting their potential effectiveness against osteoporosis.